UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 51

Sortiert nach

FLT3-mutated acute myeloid leukaemia: a new opportunity

The Lancet (British edition), 2023-05, Vol.401 (10388), p.1546-1548

2023

Link zum Volltext

Verfügbarkeit prüfen

Targeting acute myeloid leukemia through multimodal immunotherapeutic approaches

Leukemia & lymphoma, 2022-03, Vol.63 (4), p.918-927

2022

Link zum Volltext

Verfügbarkeit prüfen

BITES and CARS and checkpoints, oh my! Updates regarding immunotherapy for myeloid malignancies from the 2018 annual ASH meeting

Blood reviews, 2020-09, Vol.43, p.100654-100654, Article 100654

2020

Link zum Volltext

Verfügbarkeit prüfen

Emerging trends of therapy related myeloid neoplasms following modern cancer therapeutics in the United States

Scientific reports, 2021-12, Vol.11 (1), p.23284-23284, Article 23284

2021

Link zum Volltext

Verfügbarkeit prüfen

Cellular and Molecular Biomarkers Predictive of Response to Immunotherapy in Acute Myeloid Leukemia

Frontiers in oncology, 2022-05, Vol.12, p.826768-826768

2022

Link zum Volltext

Verfügbarkeit prüfen

Inhibitors of LSD1 as a potential therapy for acute myeloid leukemia

Expert opinion on investigational drugs, 2016-07, Vol.25 (7), p.771-780

2016

Link zum Volltext

Verfügbarkeit prüfen

Gemtuzumab ozogamicin plus standard induction chemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia

Blood cancer journal (New York), 2023-09, Vol.13 (1), p.131-4, Article 131

2023

Link zum Volltext

Verfügbarkeit prüfen

Predictors of vascular disease in myelodysplastic syndromes

EJHaem, 2020-11, Vol.1 (2), p.467-472

2020

Link zum Volltext

Verfügbarkeit prüfen

Phase 1b Trial of Anti-Immunoglobulin-like Transcript 3 Monoclonal Antibody MK-0482 Monotherapy in Relapsed/Refractory Acute Myeloid Leukemia and Chronic Myelomonocytic Leukemia

Blood, 2022-11, Vol.140 (Supplement 1), p.11759-11760

2022

Link zum Volltext

Verfügbarkeit prüfen

PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias

Blood reviews, 2021-01, Vol.45, p.100696-100696, Article 100696

2021

Link zum Volltext

Verfügbarkeit prüfen

Increased Monocytic Myeloid-Derived Suppressor Cells in the Marrow of Relapsed/Refractory Acute Myeloid Leukemia Patients Following Induction Chemotherapy

Blood, 2018-11, Vol.132 (Supplement 1), p.5270-5270

2018

Link zum Volltext

Verfügbarkeit prüfen

Impact of Race on the Mortality of Thrombotic Thrombocytopenic Purpura in the United States: A Population Study

Blood, 2022-11, Vol.140 (Supplement 1), p.5658-5659

2022

Link zum Volltext

Verfügbarkeit prüfen

PARP goes the weasel! Emerging role of PARP inhibitors in hematological malignancies

Blood reviews, 2020-05, Vol.45, p.100696-100696

2020

Link zum Volltext

Verfügbarkeit prüfen

Phase I Dose-Finding Study of Eltrombopag Following High Dose Cytarabine and Mitoxantrone Chemotherapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Blood, 2021-11, Vol.138 (Supplement 1), p.4426-4426

2021

Link zum Volltext

Verfügbarkeit prüfen

Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine and Venetoclax in Patients with Acute Myeloid Leukemia (ASPEN-05): Results from Phase 1a Dose Escalation Part

Blood, 2022-11, Vol.140 (Supplement 1), p.9046-9047

2022

Link zum Volltext

Verfügbarkeit prüfen

Low-Level Cytomegalovirus Antigenemia Promotes Protective Cytomegalovirus Antigen-Specific T Cells after Allogeneic Hematopoietic Cell Transplantation

Biology of blood and marrow transplantation, 2020-11, Vol.26 (11), p.2147-2154

2020

Link zum Volltext

Verfügbarkeit prüfen

Advancing treatment of acute myeloid leukemia: the future of FLT3 inhibitors

Expert review of anticancer therapy, 2019-03, Vol.19 (3), p.273-286

2019

Link zum Volltext

Verfügbarkeit prüfen

Phase 1b Trial of Talazoparib and Gemtuzumab Ozogamicin in Adult Patients with CD33+ Relapsed or Refractory Acute Myeloid Leukemia

Blood, 2021-11, Vol.138 (Supplement 1), p.4435-4435

2021

Link zum Volltext

Verfügbarkeit prüfen

Gilteritinib Can be Safely Combined with Atezolizumab for the Treatment of Relapsed or Refractory FLT3-Mutated AML: Results of a Phase 1 Study

Blood, 2021-11, Vol.138 (Supplement 1), p.2343-2343

2021

Link zum Volltext

Verfügbarkeit prüfen

MRD Status and ELN 2022 Predicts for Outcomes of Venetoclax + Hypomethylating Therapy in AML: Single-Center Real-World Analysis

Blood, 2022-11, Vol.140 (Supplement 1), p.9010-9012

2022

Link zum Volltext

Verfügbarkeit prüfen

Impact of Therapy on the Anamnestic Response to Seasonal Influenza Vaccination in Patients with Myeloid Malignancies

Blood, 2022-11, Vol.140 (Supplement 1), p.315-316

2022

Link zum Volltext

Verfügbarkeit prüfen

Benefits of a Pharmacist Led Oral Chemotherapy Monitoring Program for Patients with Chronic Myeloid Malignancies: A Patient Reported Outcome (PRO) Study

Blood, 2019-11, Vol.134 (Supplement_1), p.3501-3501

2019

Link zum Volltext

Verfügbarkeit prüfen

A phase II study of CPX-351 in younger patients < 60 years old with secondary acute myeloid leukemia: Trial in progress

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS7073-TPS7073

2022

Link zum Volltext

Verfügbarkeit prüfen

DNMT3A and TET2 mutant Clonal Hematopoiesis May Drive a Proinflammatory State and Predict Enhanced Response to Immune Checkpoint Inhibitors

Blood, 2021-11, Vol.138 (Supplement 1), p.4295-4295

2021

Link zum Volltext

Verfügbarkeit prüfen

Safety and Efficacy of CPX-351 in Younger Patients < 60 Years Old with Secondary Acute Myeloid Leukemia: An Updated Analysis

Blood, 2021-11, Vol.138 (Supplement 1), p.1264-1264

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 51

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(50)
Mit Volltextzugriff
(49)

Publikationsform

Artikel
(51)

Sprache

Englisch
(51)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(15)
Life Sciences & Biomedicine
(14)
Hematology
(12)
Humans
(12)
Oncology
(9)
Acute Myeloid Leukemia
(7)
Leukemia, Myeloid, Acute - Drug Therapy
(6)
Adult
(4)
Mutation
(4)
Aged
(3)
Antineoplastic Agents - Adverse Effects
(3)
Female
(3)
Immunotherapy
(3)
Leukemia, Myeloid, Acute - Diagnosis
(3)
Leukemia, Myeloid, Acute - Pathology
(3)
Male
(3)
Middle Aged
(3)
Myelodysplastic Syndrome
(3)
Animals
(2)
Antineoplastic Agents - Pharmacology
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

FLT3-mutated acute myeloid leukaemia: a new opportunity

Targeting acute myeloid leukemia through multimodal immunotherapeutic approaches

BITES and CARS and checkpoints, oh my! Updates regarding immunotherapy for myeloid malignancies from the 2018 annual ASH meeting

Emerging trends of therapy related myeloid neoplasms following modern cancer therapeutics in the United States

Cellular and Molecular Biomarkers Predictive of Response to Immunotherapy in Acute Myeloid Leukemia

Inhibitors of LSD1 as a potential therapy for acute myeloid leukemia

Gemtuzumab ozogamicin plus standard induction chemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia

Predictors of vascular disease in myelodysplastic syndromes

Phase 1b Trial of Anti-Immunoglobulin-like Transcript 3 Monoclonal Antibody MK-0482 Monotherapy in Relapsed/Refractory Acute Myeloid Leukemia and Chronic Myelomonocytic Leukemia

PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias

Increased Monocytic Myeloid-Derived Suppressor Cells in the Marrow of Relapsed/Refractory Acute Myeloid Leukemia Patients Following Induction Chemotherapy

Impact of Race on the Mortality of Thrombotic Thrombocytopenic Purpura in the United States: A Population Study

PARP goes the weasel! Emerging role of PARP inhibitors in hematological malignancies

Phase I Dose-Finding Study of Eltrombopag Following High Dose Cytarabine and Mitoxantrone Chemotherapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine and Venetoclax in Patients with Acute Myeloid Leukemia (ASPEN-05): Results from Phase 1a Dose Escalation Part

Low-Level Cytomegalovirus Antigenemia Promotes Protective Cytomegalovirus Antigen-Specific T Cells after Allogeneic Hematopoietic Cell Transplantation

Advancing treatment of acute myeloid leukemia: the future of FLT3 inhibitors

Phase 1b Trial of Talazoparib and Gemtuzumab Ozogamicin in Adult Patients with CD33+ Relapsed or Refractory Acute Myeloid Leukemia

Gilteritinib Can be Safely Combined with Atezolizumab for the Treatment of Relapsed or Refractory FLT3-Mutated AML: Results of a Phase 1 Study

MRD Status and ELN 2022 Predicts for Outcomes of Venetoclax + Hypomethylating Therapy in AML: Single-Center Real-World Analysis

Impact of Therapy on the Anamnestic Response to Seasonal Influenza Vaccination in Patients with Myeloid Malignancies

Benefits of a Pharmacist Led Oral Chemotherapy Monitoring Program for Patients with Chronic Myeloid Malignancies: A Patient Reported Outcome (PRO) Study

A phase II study of CPX-351 in younger patients < 60 years old with secondary acute myeloid leukemia: Trial in progress

DNMT3A and TET2 mutant Clonal Hematopoiesis May Drive a Proinflammatory State and Predict Enhanced Response to Immune Checkpoint Inhibitors

Safety and Efficacy of CPX-351 in Younger Patients < 60 Years Old with Secondary Acute Myeloid Leukemia: An Updated Analysis

Suchergebnisse filtern